abhd17c Antibody

What is ABHD17C and why is it important in research?

ABHD17C belongs to the α/β-hydrolase domain-containing protein 17 family, which includes three isoforms: ABHD17A, ABHD17B, and ABHD17C. These proteins function as depalmitoylases that regulate protein S-palmitoylation, a reversible lipid modification critical for protein localization and function . ABHD17C has gained significant research interest due to its role in the N-Ras palmitoylation cycle, cancer progression (particularly in pancreatic cancer), and immune regulation . Recent studies have identified ABHD17C as a potential biomarker for predicting prognosis and response to anti-PD1 therapy in pancreatic ductal adenocarcinoma (PDAC) . Its involvement in metabolic processes and immune microenvironment regulation makes it a valuable target for cancer research and therapeutic development.

What detection methods are validated for ABHD17C antibodies?

ABHD17C antibodies have been validated for several standard detection methods in molecular and cellular biology:

• Immunohistochemistry (IHC): For detection in paraffin-embedded tissue sections, with established protocols involving antigen retrieval, overnight primary antibody incubation at 4°C, and DAB substrate visualization .

• Western Blotting (WB): For protein detection in cell and tissue lysates .

• Immunocytochemistry/Immunofluorescence (ICC-IF): For cellular localization studies .

• Flow cytometry: Particularly useful when analyzing immune cell populations in the context of ABHD17C's effects on the immune microenvironment .

When selecting an antibody, researchers should verify that it has been validated for their specific application, as performance can vary considerably between different detection methods.

How should ABHD17C antibodies be stored and handled to maintain optimal activity?

For optimal preservation of antibody activity:

• Store antibodies at -20°C for long-term storage

• Avoid repeated freeze-thaw cycles by aliquoting the antibody solution upon first thaw

• For working solutions, store at 4°C for short periods (typically up to two weeks)

• Follow manufacturer's recommendations for specific storage buffers

• When preparing working dilutions, use high-quality, sterile buffers with appropriate pH (typically 7.2-7.6)

• Include carrier proteins (such as BSA) at 1-5% in dilution buffers to prevent nonspecific adsorption and loss of antibody

• Centrifuge antibody vials briefly before opening to collect solution at the bottom of the vial

Proper handling ensures consistent experimental results and extends the useful life of the antibody.

How can ABHD17C antibodies be utilized to study its role in cancer progression and immunotherapy response?

ABHD17C antibodies are powerful tools for investigating this protein's role in cancer progression and immunotherapy response through several sophisticated approaches:

• Tumor microenvironment profiling: Use immunohistochemistry with ABHD17C antibodies on patient-derived tumor samples to correlate expression levels with clinical outcomes and response to anti-PD1 therapy. Research has shown that ABHD17C overexpression significantly mediates resistance to anti-PD1 therapy and promotes pancreatic cancer progression .

• Multiplex immunofluorescence: Combine ABHD17C antibodies with markers for immune cell populations (T cells, macrophages) to investigate how ABHD17C expression affects immune cell infiltration and activation within tumors.

• Proximity ligation assays: Utilize ABHD17C antibodies with antibodies against potential interacting proteins to detect protein-protein interactions within the cellular context, helping to elucidate signaling pathways.

• ChIP-seq studies: Combine with transcription factor antibodies to investigate the regulatory mechanisms controlling ABHD17C expression in different cancer types.

• Metabolic analysis correlation: Use ABHD17C antibodies in parallel with glycolytic function experiments, as ABHD17C has been shown to enhance glycolysis and influence the tumor immune microenvironment through pH modulation .

This multifaceted approach can provide comprehensive insights into how ABHD17C influences cancer progression and immunotherapy resistance.

What considerations should be made when designing experiments to study ABHD17C's depalmitoylase activity?

When designing experiments to study ABHD17C's depalmitoylase activity, researchers should consider several critical factors:

• Substrate specificity: ABHD17C demonstrates substrate preferences, particularly toward N-Ras. Design experiments that account for this specificity, potentially including multiple substrates for comparative analysis .

• Technical approaches: Consider multiple methodologies to comprehensively assess depalmitoylase activity:

  • Pulse-chase metabolic labeling with palmitate analogs (e.g., 17-ODYA)

  • Sequential on-bead click chemistry for visualization of palmitoylated proteins

  • Site-directed mutagenesis of the catalytic serine residue (S211 in ABHD17A) to create catalytically inactive controls

• Cellular context: ABHD17C activity may vary depending on cellular context. Experiments should be performed in relevant cell lines (e.g., pancreatic cancer cell lines like PANC-1 for PDAC studies) .

• Quantification methods: Employ quantitative approaches such as:

  • RT-qPCR to confirm knockdown efficiency when using siRNA

  • Fluorescence microscopy with mCherry-tagged constructs for localization studies

  • Membrane fractionation followed by Western blotting to assess protein redistribution

• Appropriate controls: Include controls such as:

  • ABHD17C catalytic mutants (S→A mutation in the catalytic site)

  • Known ABHD17 inhibitors like ABD957

  • Other depalmitoylases (APT1, APT2) for comparative analysis

• Time course considerations: Since palmitoylation is a dynamic process, design time-course experiments to capture the kinetics of ABHD17C-mediated depalmitoylation.

How does ABHD17C expression correlate with immune infiltration in tumors, and how can antibodies help assess this relationship?

Research has revealed a significant relationship between ABHD17C expression and immune infiltration in tumors, particularly in pancreatic ductal adenocarcinoma (PDAC). ABHD17C antibodies serve as valuable tools for investigating this complex relationship through several approaches:

• Multiplex immunohistochemistry: ABHD17C antibodies can be used in conjunction with immune cell markers to simultaneously visualize and quantify ABHD17C expression and immune cell infiltration within the same tissue section. This provides spatial information about their relationship .

• Flow cytometry analysis: As documented in research, flow cytometry using ABHD17C antibodies has confirmed its role in inhibiting the formation of an immune-supportive environment in PDAC. This technique allows precise quantification of immune cell populations in relation to ABHD17C expression .

• Single-cell analysis correlation: ABHD17C antibodies can be employed in single-cell protein analysis workflows, with data integrated with single-cell RNA sequencing results. Research has utilized this integrated approach to identify ABHD17C as a metabolic and immune-related marker .

• Mechanistic studies: The research findings indicate that ABHD17C participates in metabolic processes that reshape the immunosuppressive microenvironment by downregulating pH values. ABHD17C antibodies enable the visualization of this protein in experimental settings designed to manipulate metabolic conditions, such as LDHA inhibition experiments .

• Prognostic correlation: Immunohistochemical scoring of ABHD17C expression in patient tumor samples (using scales of 0-3 for intensity and extent) allows for correlation with clinical outcomes and immunotherapy response. Research has established ABHD17C as a potential biomarker for predicting response to anti-PD1 therapy in PDAC .

The data collectively suggest that ABHD17C overexpression promotes an immunosuppressive tumor microenvironment, potentially explaining its association with resistance to immunotherapy.

What are the optimal fixation and antigen retrieval protocols for ABHD17C immunohistochemistry?

For optimal ABHD17C detection in tissue samples, the following protocol has been validated in research settings:

• Fixation:

  • Use 10% neutral-buffered formalin for 24-48 hours at room temperature

  • Process tissues and embed in paraffin following standard histological procedures

• Sectioning:

  • Cut paraffin sections at 4-5 μm thickness

  • Mount on positively charged slides

• Deparaffinization and Rehydration:

  • Deparaffinize sections in xylene (3 changes, 5 minutes each)

  • Rehydrate through graded alcohols (100%, 95%, 70%, 50%) to water

• Antigen Retrieval (critical step):

  • Heat-mediated antigen retrieval in a pressure cooker for 3 minutes

  • Use citrate buffer (10 mM, pH 6.0) or EDTA buffer (1 mM, pH 8.0)

  • Allow slides to cool in the buffer for 20 minutes at room temperature

• Blocking and Primary Antibody Incubation:

  • Block endogenous peroxidase activity with 3% hydrogen peroxide for 10 minutes

  • Block non-specific binding with 5% normal serum

  • Incubate with primary anti-ABHD17C antibody overnight at 4°C

  • Optimal dilution should be determined empirically but typically ranges from 1:100 to 1:500

• Detection:

  • Incubate with peroxidase-conjugated secondary antibody at 37°C for 30 minutes

  • Develop using DAB substrate kit

  • Counterstain with hematoxylin, dehydrate, and mount

• Scoring System:

  • Evaluate staining intensity on a scale of 0 (negative), 1 (low), 2 (medium), or 3 (high)

  • Score extent of staining as 0 (0% stained), 1 (1-25% stained), 2 (26-50% stained), or 3 (51-100% stained)

  • Analyze five random fields at 20× magnification

This protocol has been successfully employed in research studies examining ABHD17C expression in pancreatic cancer tissues.

What are the recommended protocols for transfection and siRNA-mediated knockdown of ABHD17C?

Based on established research protocols, here are the recommended approaches for transfection and siRNA-mediated knockdown of ABHD17C:

siRNA-Mediated Knockdown Protocol:

• Cell Preparation:

  • Culture cells in appropriate medium (e.g., DMEM with 10% FBS, 4 mM L-glutamine, and 1 mM sodium pyruvate)

  • Maintain cells at 37°C in a humidified incubator with 5% CO₂

  • Plate cells to reach 70-80% confluence on the day of transfection

• siRNA Transfection (HEK293T cells protocol):

  • Day 1: Transfect cells with siRNA using 9 μL Lipofectamine RNAiMax

  • For efficient knockdown of all three ABHD17 isoforms, use siRNA pools targeting ABHD17A, ABHD17B, and ABHD17C

  • Single isoform knockdown can be performed with isoform-specific siRNAs

  • Final siRNA concentration: 100 nM per transfection

• cDNA Co-transfection (if required for experimental design):

  • Day 3: Co-transfect 1 μg of cDNA (e.g., encoding a substrate protein) using 4 μL Lipofectamine 2000

  • This approach allows for simultaneous knockdown of ABHD17C and expression of a protein of interest

• Double Knockdown Approach (for enhanced silencing):

  • Transfect cells with siRNA on days 1 and 3 using 5 μL Lipofectamine 2000 per transfection

  • Co-transfect 1 μg of cDNA with the siRNA on day 3

  • Perform experimental analyses on day 4, approximately 20 hours following co-transfection

• Knockdown Validation:

  • Collect cells in TRIzol reagent 72 hours post-transfection

  • Extract total RNA using an appropriate RNA isolation kit

  • Synthesize cDNA using 1 μg of RNA per sample

  • Perform RT-qPCR with gene-specific primers for ABHD17C

  • Normalize to housekeeping genes (e.g., β-actin)

  • Determine knockdown efficiency using the ΔΔCt method

This protocol has been demonstrated to achieve efficient silencing of ABHD17 isoforms and is suitable for subsequent functional studies.

How can researchers optimize Western blot protocols for ABHD17C detection?

Optimizing Western blot protocols for ABHD17C detection requires attention to several critical factors:

Sample Preparation:

• Prepare lysates in TEA lysis buffer (50 mM triethanolamine pH 7.4, 150 mM NaCl, 1% Triton X-100, with protease inhibitors)

• For membrane proteins like ABHD17C, include brief sonication (3-5 pulses) to ensure complete solubilization

• Clarify lysates by centrifugation at 16,000 × g for 10 minutes at 4°C

• Determine protein concentration using Bradford or BCA assay

• Prepare samples in Laemmli buffer with reducing agent and heat at 70°C for 10 minutes (avoid boiling as it may cause aggregation of membrane proteins)

Gel Electrophoresis and Transfer:

• Load 20-50 μg protein per lane on 10-12% SDS-PAGE gels

• Include positive controls and molecular weight markers

• Transfer to PVDF membranes (preferable over nitrocellulose for hydrophobic proteins)

• Use wet transfer systems at 100V for 1 hour or 30V overnight at 4°C

• Verify transfer efficiency with reversible protein stains

Immunodetection:

• Block membranes in 5% non-fat dry milk or 3-5% BSA in TBST for 1 hour at room temperature

• Incubate with anti-ABHD17C primary antibody at optimized dilution (typically 1:500 to 1:2000) overnight at 4°C

• Wash extensively with TBST (4 × 5 minutes)

• Incubate with HRP-conjugated secondary antibody (1:5000 to 1:10000) for 1 hour at room temperature

• Wash extensively with TBST (4 × 10 minutes)

• Develop using enhanced chemiluminescence and image using a digital imaging system

Critical Optimization Points:

• Antibody validation: Confirm specificity using siRNA knockdown samples as negative controls

• Membrane blocking: Test both milk and BSA as blocking agents, as some antibodies perform better with one vs. the other

• Dilution optimization: Perform a dilution series of primary antibody to determine optimal signal-to-noise ratio

• Stripping and reprobing: If detecting multiple proteins, optimize stripping conditions or prepare duplicate blots

• Expected molecular weight: ABHD17C should be detected at approximately 24-27 kDa, but post-translational modifications may alter migration

These optimized protocols incorporate methodologies from published research on ABHD17 proteins and should provide reliable detection of ABHD17C in Western blot applications.

What are common challenges in ABHD17C antibody applications and how can they be addressed?

Researchers may encounter several challenges when working with ABHD17C antibodies. Here are common issues and their solutions:

1. Low Signal Intensity:

• Challenge: Weak or undetectable ABHD17C signal in IHC or Western blotting.

• Solutions:

  • Optimize antibody concentration through titration experiments

  • Enhance antigen retrieval (for IHC) by adjusting pH, buffer composition, or heating time

  • Increase protein loading amount for Western blots

  • Try alternative detection systems with higher sensitivity

  • Extend primary antibody incubation time (overnight at 4°C)

  • Ensure sample preparation preserves protein integrity

2. Cross-Reactivity:

• Challenge: ABHD17C antibodies may cross-react with other ABHD17 family members (ABHD17A, ABHD17B) due to sequence homology.

• Solutions:

  • Validate antibody specificity using siRNA knockdown controls for each isoform

  • Include recombinant protein controls for each isoform

  • Consider using monoclonal antibodies with validated epitope specificity

  • Perform pre-absorption controls with recombinant proteins

3. Background Signal:

• Challenge: High background making specific signal difficult to distinguish.

• Solutions:

  • Optimize blocking conditions (test different blockers like BSA, normal serum, or commercial blocking buffers)

  • Increase washing steps duration and frequency

  • Titrate secondary antibody to minimize non-specific binding

  • Include appropriate negative controls (isotype controls, secondary-only controls)

  • For IHC, quench endogenous peroxidase/phosphatase activity thoroughly

4. Inconsistent Results:

• Challenge: Variable staining patterns between experiments.

• Solutions:

  • Standardize protocols for sample preparation, antibody dilution, and incubation times

  • Maintain consistent lot numbers of antibodies when possible

  • Include positive control samples in each experiment

  • Prepare larger volumes of working antibody solutions to use across multiple experiments

5. Detection in Complex Samples:

• Challenge: Difficulty detecting endogenous ABHD17C in certain tissues or cell types.

• Solutions:

  • Consider enrichment strategies like immunoprecipitation before detection

  • Use signal amplification systems (tyramide signal amplification for IHC, enhanced chemiluminescence for WB)

  • Optimize lysis conditions to ensure complete solubilization of membrane-associated ABHD17C

Careful optimization and inclusion of appropriate controls are essential for successful ABHD17C antibody applications.

How can researchers verify the specificity of their ABHD17C antibody?

Verifying antibody specificity is crucial for obtaining reliable research results. For ABHD17C antibodies, consider these comprehensive verification approaches:

1. Genetic Knockdown/Knockout Controls:

• Perform siRNA-mediated knockdown of ABHD17C and test antibody reactivity

• Include siRNA controls for ABHD17A and ABHD17B to confirm isoform specificity

• If available, use CRISPR/Cas9-generated knockout cell lines as negative controls

• Compare signal intensity between wild-type and knockdown/knockout samples using Western blot or immunofluorescence

2. Overexpression Systems:

• Transfect cells with ABHD17C expression constructs

• Include tagged versions (FLAG, mCherry) that can be detected with alternative antibodies

• Compare staining patterns between ABHD17C antibody and tag-specific antibodies

• Include overexpression of related family members (ABHD17A, ABHD17B) to test cross-reactivity

3. Peptide Blocking:

• Pre-incubate ABHD17C antibody with excess immunizing peptide

• Compare staining with and without peptide blocking

• Specific antibody signal should be significantly reduced after peptide blocking

4. Multiple Antibody Validation:

• Compare results from multiple ABHD17C antibodies targeting different epitopes

• Consistent results across different antibodies increase confidence in specificity

5. Mass Spectrometry Validation:

• Perform immunoprecipitation with ABHD17C antibody

• Analyze precipitated proteins by mass spectrometry

• Confirm the presence of ABHD17C peptides in the immunoprecipitated sample

6. Tissue/Cell Type Expression Pattern:

• Compare antibody staining patterns with known ABHD17C mRNA expression data

• Discrepancies between protein and mRNA expression patterns may indicate specificity issues

7. Recombinant Protein Controls:

• Test antibody against purified recombinant ABHD17A, ABHD17B, and ABHD17C

• Determine cross-reactivity and relative affinity for each isoform

8. Function-Blocking Experiments:

• Assess whether the antibody can inhibit known ABHD17C functions, such as depalmitoylation activity

• Compare with specific small molecule inhibitors like ABD957

Implementing multiple validation strategies provides the highest confidence in antibody specificity and experimental results.

How should researchers interpret variations in ABHD17C expression patterns across different tumor types?

Interpreting variations in ABHD17C expression across tumor types requires a nuanced approach that considers multiple factors:

1. Biological Significance Assessment:

• Compare ABHD17C expression levels with established clinical parameters such as tumor stage, grade, and patient survival data

• Research has identified ABHD17C as an independent prognostic evaluation index for PDAC patients

• Determine whether ABHD17C expression correlates with specific molecular subtypes of the cancer being studied

• Consider whether expression changes represent cause or consequence of tumor progression

2. Contextual Interpretation Framework:

• Evaluate ABHD17C in the context of its known functions:

  • As a depalmitoylase regulating N-Ras localization

  • As a metabolic regulator affecting glycolysis in tumor cells

  • As a modulator of the immune microenvironment

• Determine whether different tumors show variations in these functional pathways

3. Technical Considerations:

• Use standardized scoring systems for immunohistochemistry (0-3 scales for intensity and extent)

• Ensure consistent staining protocols across different tumor types

• Validate findings with orthogonal methods (RT-qPCR, Western blotting)

• Consider the heterogeneity within tumor samples by analyzing multiple regions

4. Comparative Analysis Strategies:

• Create a data table comparing ABHD17C expression across different tumor types, including:

  Tumor Type	ABHD17C Expression Level	Association with Prognosis	Correlation with Immune Infiltration	Metabolic Features
  PDAC	High in aggressive cases	Negative prognostic factor	Immunosuppressive	Enhanced glycolysis
  Other tumor types...	(Data from your research)

• Analyze expression in relation to other ABHD17 family members (ABHD17A, ABHD17B)

• Compare with expression in corresponding normal tissues

5. Functional Implications:

• Assess whether ABHD17C expression correlates with:

  • Response to immunotherapy (particularly anti-PD1)

  • Alterations in tumor metabolism

  • Changes in palmitoylation status of key oncoproteins

• Consider therapeutic implications of expression patterns

6. Integration with Broader Molecular Profiling:

• Correlate ABHD17C expression with genomic alterations, transcriptomic signatures, and proteomic profiles

• Determine whether ABHD17C expression is associated with specific driver mutations or oncogenic pathways

This multifaceted approach to interpreting ABHD17C expression variations can provide valuable insights into its role in cancer biology and potential as a therapeutic target or biomarker.

How might ABHD17C antibodies be utilized in studying its role in neurodegenerative diseases?

While ABHD17C has been primarily studied in cancer contexts, its fundamental role as a depalmitoylase suggests potential significance in neurodegenerative diseases. Researchers can utilize ABHD17C antibodies to explore this emerging area through several approaches:

• Protein localization in neuronal contexts: ABHD17C antibodies can be used for immunohistochemistry and immunofluorescence studies in brain tissues to examine expression patterns in different neuronal populations and how these change in neurodegenerative conditions .

• Palmitoylation regulation of neuronal proteins: Since ABHD17 proteins regulate the palmitoylation status of crucial neuronal proteins, antibodies can help investigate interactions between ABHD17C and potential neuronal substrates through co-immunoprecipitation studies. The protocols established for N-Ras palmitoylation studies provide a framework for similar investigations with neuronal proteins .

• Synapse formation and maintenance: Researchers can employ ABHD17C antibodies in studying synaptic protein palmitoylation, which is critical for proper synapse formation and function. Immunofluorescence colocalization studies with synaptic markers can reveal potential roles at the synapse.

• Post-translational modifications: Combine ABHD17C antibodies with phospho-specific or ubiquitin-specific antibodies to investigate how this protein is regulated in neuronal contexts, particularly under stress conditions associated with neurodegeneration.

• Microglial function: Given ABHD17C's role in immune regulation in cancer contexts , investigate its potential role in microglial function within the CNS using flow cytometry and immunofluorescence with ABHD17C antibodies.

• Therapeutic target assessment: As ABHD17 inhibition has been proposed as a potential therapeutic approach , ABHD17C antibodies can help evaluate the consequences of such inhibition in neuronal systems, potentially through ex vivo brain slice cultures or primary neuronal cultures.

This research direction represents an important expansion from cancer applications into neuroscience, potentially revealing new roles for ABHD17C in brain function and pathology.

What methods can be used to investigate ABHD17C's role in protein palmitoylation dynamics?

Investigating ABHD17C's role in protein palmitoylation dynamics requires sophisticated methodological approaches. Researchers can employ the following techniques, utilizing ABHD17C antibodies as key components:

• Metabolic Labeling with Palmitate Analogs:

  • Use click chemistry-compatible palmitate analogs (e.g., 17-ODYA) to metabolically label palmitoylated proteins

  • Perform pulse-chase experiments to track palmitoylation dynamics

  • Compare palmitoylation patterns in control vs. ABHD17C-manipulated conditions (knockdown, overexpression)

  • Visualization through sequential on-bead CuAAC/click chemistry after immunoprecipitation

• Acyl-Biotin Exchange (ABE) and Acyl-Resin-Assisted Capture (Acyl-RAC):

  • These complementary biochemical techniques detect protein S-palmitoylation through selective thioester bond manipulation

  • Use ABHD17C antibodies to immunoprecipitate the enzyme from cell lysates

  • Identify ABHD17C-interacting proteins that undergo palmitoylation changes

  • Quantify changes in substrate palmitoylation levels following ABHD17C manipulation

• Live-Cell Imaging of Palmitoylation Dynamics:

  • Utilize fluorescently tagged constructs (e.g., ABHD17A/B/C-mCherry) to track enzyme localization

  • Combine with fluorescently tagged substrate proteins

  • Perform Fluorescence Recovery After Photobleaching (FRAP) to measure protein mobility, which often correlates with palmitoylation status

  • Conduct live-cell imaging following manipulation of ABHD17C levels or activity

• Palmitoylation Site Mapping:

  • Identify specific palmitoylation sites on substrate proteins using mass spectrometry

  • Compare site occupancy with and without ABHD17C manipulation

  • Create site-specific mutants to validate functional significance

• Small Molecule Inhibitor Studies:

  • Utilize ABHD17 inhibitors like ABD957

  • Monitor changes in substrate palmitoylation following inhibitor treatment

  • Use ABHD17C antibodies to confirm target engagement in cells through cellular thermal shift assays (CETSA) or related approaches

• Integrative Multi-Omics Approach:

  • Combine proteomics to identify palmitoylated proteins

  • Use transcriptomics to assess downstream effects of altered palmitoylation

  • Apply ABHD17C antibodies for ChIP-seq to identify potential transcriptional regulatory functions

These methodologies provide a comprehensive toolkit for investigating ABHD17C's role in protein palmitoylation dynamics, contributing to our understanding of this critical post-translational modification in normal physiology and disease states.

How can ABHD17C antibodies be used in developing targeted cancer therapies?

ABHD17C antibodies offer valuable applications in developing targeted cancer therapies, serving as tools for biomarker validation, therapeutic target assessment, and companion diagnostic development:

• Patient Stratification Biomarker Development:

  • Validate ABHD17C as a predictive biomarker for anti-PD1 therapy response in PDAC and potentially other cancers

  • Develop immunohistochemistry-based diagnostic assays using standardized scoring systems (0-3 scales for intensity and extent)

  • Create tissue microarray studies across patient cohorts to correlate ABHD17C expression with treatment outcomes

  • Research has already identified ABHD17C as a potential biomarker for predicting the prognosis and response to anti-PD1 therapy in PDAC

• Target Validation for Drug Development:

  • Use ABHD17C antibodies to confirm target engagement of potential ABHD17C inhibitors

  • Employ cellular thermal shift assays (CETSA) with ABHD17C antibodies to assess direct binding of small molecules

  • Validate on-target effects of ABHD17C inhibitors through downstream functional readouts

  • Monitor changes in palmitoylation status of key substrates following inhibitor treatment

• Combination Therapy Development:

  • Investigate synergistic effects between ABHD17C inhibition and immunotherapies

  • Research has shown that ABHD17C overexpression mediates resistance to anti-PD1 therapy, suggesting inhibition could enhance immunotherapy efficacy

  • Explore combinations with metabolic inhibitors, as ABHD17C has been linked to glycolytic function

  • Use ABHD17C antibodies to monitor changes in expression and localization following various treatment modalities

• Antibody-Drug Conjugate (ADC) Exploration:

  • Assess the potential of ABHD17C as an ADC target if surface expression can be confirmed in certain cancer contexts

  • Evaluate internalization kinetics of antibodies against external epitopes

  • Optimize linker-payload systems for potential ADC development

• Functional Modulation Therapeutic Approaches:

  • Develop function-blocking antibodies that could directly inhibit ABHD17C's depalmitoylase activity

  • Screen for antibodies that specifically block interaction with key substrates

  • Validate efficacy using assays that measure palmitoylation dynamics

• Therapeutic Monitoring Applications:

  • Utilize ABHD17C antibodies for pharmacodynamic biomarker development

  • Monitor changes in ABHD17C expression or activity following treatment

  • Develop liquid biopsy applications if ABHD17C or its palmitoylated substrates are detectable in circulation

These applications highlight the multifaceted potential of ABHD17C antibodies in cancer therapeutic development, spanning from biomarker validation to direct therapeutic targeting and companion diagnostic development.